CoChat

Polycystic Ovary Syndrome: What's in a Name?

Open access
Azziz, Ricardo · 2014 · The Journal of Clinical Endocrinology & Metabolism
Cited by 39

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Assigning names to new concepts in both general and medical knowledge is frequently problematic. Medical disorders have been primarily named after the first (or more often, the first to be recognized) individuals to describe its features (eg, Asperger's syndrome), or perhaps after some clinical finding, now historic, and perhaps even tangential in nature (eg, systemic lupus erythematosus). Such names are frequently not intuitive and do not allow patients or their doctors to immediately understand what the disorder is all about without having to memorize the link first. But the increasing need for medical efficiency and the growing number of conditions today call for medical disorder names that are readily informative and almost instinctual in nature. And that is where we are with the disorder that we today know as the “polycystic ovary syndrome” (also known as polycystic ovarian syndrome) or PCOS, previously known as the “polycystic ovary disease” (PCOD), and even before that as the “Stein-Leventhal syndrome.” We now know that this disorder is extraordinarily common, affecting between 6 and 20% of reproductive-age women depending on the diagnostic criteria used (because there is more than one). It was originally named for the first individuals to report on symptoms associated with the syndrome (1), and then for the salient physical finding first observed (polycystic ovaries, a term coined by Stein and Leventhal). Recently, a National Institutes of Health (NIH) consensus meeting [NIH Office of Disease Prevention: Evidence-based Methodology Workshop on Polycystic Ovary Syndrome (PCOS), December 3–5, 2012] was convened to try and bring clarity to the field of study (2). Among their recommendations, members of the panel noted, “We believe the name 'PCOS' is a distraction and an impediment to progress. It causes confusion and is a barrier to effective education of clinicians and communication with the public and research funders.” The panel further stated, “It is time to expeditiously assign a name that reflects the complex… interactions that characterize the syndrome—and their reproductive implications.” This investigator strongly agrees with this recommendation. As we would expect, there have been prior efforts at renaming the disorder, including the change from Stein-Leventhal syndrome to PCOD and then to PCOS (because the disorder does not appear to be a specific disease). Lobo (3) proposed changing the name of the disorder to “hyperandrogenic chronic anovulation” to reflect the underlying and generally unique condition associated with the disorder—hyperandrogenism. More recently, Behera et al suggested changing the name of PCOS to “estrogenic ovulatory dysfunction” or “functional female hyperandrogenism” (4). Notably, both of these recommendations centered on naming the disorder around generalities concerning the condition itself, although paradoxically perhaps they were too general to be useful enough. And neither had the force of authority behind them—unlike the NIH panel recommendations. Name change is not new, of course. It has already occurred for a number of diseases or disorders, eg, mongolism to Down syndrome, manic depression to bipolar disorder, testicular feminization to androgen insensitivity syndrome, multiple personality to dissociative identity disorder. And a few have paradoxically changed their names to those of individuals, such as changing senile dementia to Alzheimer's disease and leprosy to Hansen's disease. Names have been changed for food products. The Chinese gooseberry was renamed kiwi because New Zealand farmers wanted to sell it. Although the fruit originated in the Yangtzee Valley in northern China, the strategy has been pretty successful because New Zealand is now one of the largest exporters of kiwifruit to the United States. Also in the United States, where we can be squeamish about what we eat, dolphinfish were renamed mahi-mahi because Americans don't want to eat dolphins—although dolphinfish are not at all mammals. And the Patagonian toothfish was renamed Chilean sea bass, opening a whole new market in the United States for this fish, a naming strategy so successful that the species has since been overfished. Corporations have changed their names as well; eg, Blue Ribbon Sports to Nike, Standard Oil Company to Exxon Mobile, and Jerry's Guide to the World Wide Web to Yahoo. In the rapidly changed world of business, however, not all changes were for the better—or were even successful—providing lessons for us as we contemplate changing the name of PCOS. In 2002, Royal Mail in the United Kingdom renamed itself Consignia. This did not go well with the average British consumer who had no idea what “consignia” even meant. (It's a derivative of the Italian word “consegna” meaning “act of delivering”). The name was quietly phased out over the next 2 years. And in 2009, Kraft Foods renamed the venerable British toast spread Vegemite as iSnack 2.0. But before you ask what that name ev

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2013-3996

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 39

Metadata

Authors
Azziz, R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2014-04-01
Volume
99
Issue
4
Pages
1142-1145
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2081550159
Cited by
39
References
6
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polycystic Ovary Syndrome: What's in a Name? https://app.cochat.ai/papers/10.1210/jc.2013-3996
The paper
Azziz, R. (2014). Polycystic Ovary Syndrome: What's in a Name? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-3996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.